- Q2 2024 Medivir AB Earnings Call Transcript5 days agokr2.93Earnings
- Q4 2023 Medivir AB Earnings Call TranscriptFeb 15, 2024kr3.57Earnings
- Medivir AB to Discuss the Updated Data in Advanced Hepatocellular Carcinoma Call TranscriptJan 23, 2024
- Q3 2023 Medivir AB Earnings Call TranscriptOct 27, 2023kr7.35 (+5.00%)Earnings
- Q2 2023 Medivir AB Earnings Call TranscriptAug 18, 2023kr7Earnings
- Q1 2023 Medivir AB Earnings Call TranscriptApr 27, 2023kr7.92Earnings
- Q4 2022 Medivir AB Earnings Call TranscriptFeb 15, 2023kr7.92Earnings
- Medivir AB at Redeye Fight Cancer Day (Virtual) TranscriptJan 19, 2023
- Q3 2022 Medivir AB Earnings Call TranscriptNov 03, 2022kr7.92Earnings
- Q2 2022 Medivir AB Earnings Call TranscriptAug 19, 2022kr8.05Earnings
- Q1 2022 Medivir AB Earnings Call TranscriptApr 28, 2022kr8.05Earnings
- Q4 2021 Medivir AB Earnings Call TranscriptFeb 15, 2022kr8.35Earnings
- Q3 2021 Medivir AB Earnings Call TranscriptNov 03, 2021kr9.99Earnings
- Medivir AB to Discuss Update on the Progress and Plans for the MIV-818 Program Call TranscriptSep 16, 2021
- Q2 2021 Medivir AB Earnings Call TranscriptAug 19, 2021kr10.56 (-5.55%)Earnings
- Q1 2021 Medivir AB Earnings Call TranscriptApr 28, 2021kr7.88Earnings
- Q4 2020 Medivir AB Earnings Call TranscriptFeb 26, 2021kr8.66Earnings
- Medivir AB to Discuss Exclusive Licensing Agreement with IGM Biosciences for Birinapant Call TranscriptJan 12, 2021
- Q3 2020 Medivir AB Earnings Call TranscriptNov 10, 2020kr14.06Earnings
- Q2 2020 Medivir AB Earnings Call TranscriptAug 20, 2020kr16.6Earnings
- Q1 2020 Medivir AB Earnings Call TranscriptMay 05, 2020kr11.44Earnings
- Medivir AB R&D Day TranscriptMar 02, 2020
- Q4 2019 Medivir AB Earnings Call TranscriptFeb 13, 2020kr14.56Earnings
- Q3 2019 Medivir AB Earnings Call TranscriptNov 27, 2019kr21.55Earnings
- Q2 2019 Medivir AB Earnings Call TranscriptAug 28, 2019kr24.68Earnings
- Medivir AB to Discuss the Development of Phase IA Study with MIV-818 Call TranscriptJun 13, 2019
- Q1 2019 Medivir AB Earnings Call TranscriptMay 03, 2019kr19.08Earnings
Medivir AB R&D Day Transcript
()- -
Good morning, and welcome to Medivir's R&D day. It's nice to see that so many of you have decided to come and listen to us live, but I know that we also have a lot of attendees that have connected through the web. I hope that we can offer you an exciting day, we think so. It will be a mix of educational and new data presentations. So I think the combination will really teach us a lot about liver cancer, a lot about MIV-818 and the opportunities that we see there and with other assets that we have.
Let me first say that it's good to take a look at this note and the forward-looking statements that are included in that. This is a slide that we always have, by the way. So the agenda today really starts with Dr. Evans, who will provide us with a lecture on primary liver cancer, and I'll come back to that later on. I think it's a great introduction of the day. Then Christina Herder, who is our EVP and Chief Operational Officer, will talk about the market for liver cancer drugs, which I think is
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)